Sanara MedTech (SMTI) FDA Approvals $23.17 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$23.40 +0.23 (+0.99%) As of 05/22/2026 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Sanara MedTech's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Sanara MedTech (SMTI). Over the past two years, Sanara MedTech has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as CellerateRX. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. CellerateRX FDA Regulatory Events CellerateRX is a drug developed by Sanara MedTech for the following indication: Surgical Powder in the Management of Spine Surgery Wounds. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - March 11,2026Publication Drug: CellerateRXAnnounced Date: March 11, 2026Indication: Surgical Powder in the Management of Spine Surgery WoundsAnnouncementSanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics.AI SummarySanara MedTech announced a peer‑reviewed study in the Journal of Medical Economics that evaluated the economic and clinical value of CellerateRX® Surgical Powder. Researchers used economic modeling to compare two groups of high‑comorbidity patients having complex spinal surgery: those who received CellerateRX as an adjunct to standard wound care and those who received standard care alone. The study tracked postoperative complications, hospital readmissions, and surgical revisions over one year. Clinical benefits were measured in quality‑adjusted life years (QALYs) and direct medical costs were expressed in 2025 U.S. dollars. The study found that adding CellerateRX led to both better health outcomes and overall cost savings versus standard care alone. Authors concluded CellerateRX can be a value‑enhancing part of the spine surgery care pathway, especially for patients who face higher risk of complications, by reducing complications, readmissions and costly revision procedures. Read Announcement Sanara MedTech FDA Events - Frequently Asked Questions Has Sanara MedTech received FDA approval? As of now, Sanara MedTech (SMTI) has not received any FDA approvals for its therapy in the last two years. What drugs has Sanara MedTech submitted to the FDA? In the past two years, Sanara MedTech (SMTI) has reported FDA regulatory activity for CellerateRX. What is the most recent FDA event for Sanara MedTech? The most recent FDA-related event for Sanara MedTech occurred on March 11, 2026, involving CellerateRX. The update was categorized as "Publication," with the company reporting: "Sanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics." What conditions do Sanara MedTech's current drugs treat? Currently, Sanara MedTech has one therapy (CellerateRX) targeting the following condition: Surgical Powder in the Management of Spine Surgery Wounds. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AC Immune FDA EventsAgios Pharmaceuticals FDA EventsAssembly Biosciences FDA EventsBriacell Therap FDA EventsBioLineRx FDA EventsFibroBiologics FDA EventsGilead Sciences FDA EventsOncolytics Biotech FDA EventsRegeneron Pharmaceuticals FDA EventsAbbVie FDA EventsMerck & Co., Inc. FDA EventsAgenus FDA EventsAdagio Medical FDA EventsAktis Oncology FDA EventsAkari Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies SS Innovations International FDA Events Spyglass Pharma FDA Events Brainsway FDA Events NeuroPace FDA Events Tactile Systems Technology FDA Events Delcath Systems FDA Events ClearPoint Neuro FDA Events Sight Sciences FDA Events Profound Medical FDA Events Orchestra BioMed FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:SMTI last updated on 3/11/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanara MedTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - March 11,2026Publication Drug: CellerateRXAnnounced Date: March 11, 2026Indication: Surgical Powder in the Management of Spine Surgery WoundsAnnouncementSanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics.AI SummarySanara MedTech announced a peer‑reviewed study in the Journal of Medical Economics that evaluated the economic and clinical value of CellerateRX® Surgical Powder. Researchers used economic modeling to compare two groups of high‑comorbidity patients having complex spinal surgery: those who received CellerateRX as an adjunct to standard wound care and those who received standard care alone. The study tracked postoperative complications, hospital readmissions, and surgical revisions over one year. Clinical benefits were measured in quality‑adjusted life years (QALYs) and direct medical costs were expressed in 2025 U.S. dollars. The study found that adding CellerateRX led to both better health outcomes and overall cost savings versus standard care alone. Authors concluded CellerateRX can be a value‑enhancing part of the spine surgery care pathway, especially for patients who face higher risk of complications, by reducing complications, readmissions and costly revision procedures. Read Announcement
